서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 76

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-09
Management of gastric lymphoma with chemotherapy alone

Oh, D. Y.; Choi, I. S.; Kim, J. H.; Rhu, M. H.; Kim, T. Y.; Heo, Dae Seog; Bang, Y. J.; Kim, N. K.

Leukemia and Lymphoma, Vol.46 No.9, pp.1329-1335

DOI
2011-07
Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib
DOI
2013-10
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Cortes, J.; Baselga, J.; Im, Y. -H.; Im, S. -A.; Pivot, X.; Ross, G.; Clark, E.; Knott, A.; Swain, S. M.

Annals of Oncology, Vol.24 No.10, pp.2630-2635

DOI
2013-11
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
DOI
2013-12
The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer
view fileDOI
2014-04
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis

Lee, June-Koo; Hahn, Seokyung; Kim, Dong-Wan; Suh, Koung Jin; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog

JAMA - Journal of the American Medical Association, Vol.311 No.14, pp.1430-1437

DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
view fileDOI
2015-10
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
DOI
2015-11
Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer
DOI
2016-05
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
DOI
2016-07
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
DOI
2016-08
Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial
DOI
2016-12
Revision surgeries following artificial disc replacement of cervical spine

Park, Jong-Beom; Chang, Han; Yeom, Jin S.; Suk, Kyung-Soo; Lee, Dong-Ho; Lee, Jae Chul

Acta Orthopaedica et Traumatologica Turcica, Vol.50 No.6, pp.610-618

DOI
2017-02
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
DOI
2017-04
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
DOI
2017-05
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
DOI
2017-05
Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size
DOI
2017-10
Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
DOI
2017-12
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

ExteNET Study Group; Im, Seock Ah

The Lancet Oncology, Vol.18 No.12, pp.1688-1700

DOI
2018-01
Topical tacrolimus 0.03% for maintenance therapy in steroid-dependent, recurrent phlyctenular keratoconjunctivitis

Yoon, Chang Ho; Kim, Mee Kum; Oh, Joo Youn

Cornea, Vol.37 No.2, pp.168-171

DOI
2018-03
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DOI
2018-03
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
DOI
2018-03
Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE
DOI
2018-03
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
DOI
2018-04
Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer
DOI
2018-04
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
DOI
2018-04
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
DOI
2018-05
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
DOI
2018-06
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
DOI
2018-07
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial
DOI
2018-09
Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials
DOI
2018-11
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
DOI
2019-04
Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients

Lee, Ji Su; Park, Hyun-sun; Yoon, Hyun-Sun; Cho, Soyun

Annals of Dermatology, Vol.31 No.2, pp.139-145

DOI
2019-04
Proportion of aspiration pneumonia cases among patients with community-acquired pneumonia: A single-center study in Korea

Jeon, Inpyo; Jung, Gwang Pyo; Seo, Han Gil; Ryu, Ju Seok; Han, Tai Ryoon; Oh, Byung-Mo

Annals of Rehabilitation Medicine, Vol.43 No.2, pp.121-128

DOI
2019-04
Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
DOI
2019-05
Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study
DOI
2019-07
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
DOI
2019-07
Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): Study protocol for a randomized controlled trial
DOI
2019-09
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
1 2